Loading…
← CockpitCompetitor Analysis › KRSA Korsana Biosciences, Inc.Open in the cockpit ↗

Korsana Biosciences, Inc.KRSACompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops antibody therapies for Alzheimer's and neurodegenerative disease using a blood-brain-barrier shuttle platform.

Momentum leader 93
Mkt cap
$1.52B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$6.00M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 14.3%
Hurdle
n/a
no reverse DCF
Next earnings
126 days
24 Mar 2027
Close · USD$33.27
1D+2.4%
1W+4.5%
1M+7.2%
3M+16.8%
6M+54.3%
YTD+274.2%
1Y+241.9%
ATR %7.0%
Beta1.64
52w lowhigh44.0% off high

What Korsana Biosciences does

Develops antibody therapies for Alzheimer's and neurodegenerative disease using a blood-brain-barrier shuttle platform.

Has no product or revenue, so it relies on the cash it holds and later share sales, and everything depends on whether its lead antibody can reach the brain better than existing treatments. It reached the stock market in 2026 by merging with Cyclerion, an already listed company.

Products and services

  • KRSA-028 (anti-amyloid antibody with brain-shuttle technolog

Customers

  • Neurologists (post-approval)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Neurodegenerative disease antibody…

What could go right

  • Differentiated brain-penetration technology
  • Well-funded following a 2026 reverse merger with Cyclerion

What could go wrong

  • Crowded and high-failure-rate Alzheimer's drug field
  • Early-stage clinical risk

Moat: narrow (IP / patents, process know-how). THETA platform aims for better brain penetration than approved amyloid antibodies, but is unproven in the clinic.

Headquarters: Boston, Massachusetts, US · Founded: 2024 · Employees: 1

Named competitors

Korsana Biosciences at a glance

Size Korsana Biosciences (KRSA) is a United States Health Care company (Biotechnology) with a market value of $1.52B, the 1968th largest of 3,085 United States companies the cockpit tracks. Shares closed at $33.27 on 18 Nov 2026.

Performance Over six months the shares gained 54.3%, against -6.9% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 20 in its peer set.

Growth Revenue fell 64.1% over the last twelve months (peer median +25.4%); the operating margin is -5,277.3% (peer median -5.7%).

Valuation It trades at 1,058.7× enterprise value to sales against a peer median of 10.1× (2nd most expensive of 18).

Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012515021 May 202621 Aug 202618 Nov 2026KRSA 150Peer median 92
Six months, rebased to 100: Korsana Biosciences against the median of its 20 peers (local-currency closes).

Korsana Biosciences financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.02M$2.07M$2.00M$0$297,000
Revenue growth—+4%—-100%—
Gross profitn/an/an/a$0$232,000
EBITDA-$54.1M-$4.97M-$3.63M-$9.65M-$18.5M
Net income-$52.2M-$3.53M-$3.06M-$21.0M-$44.1M
Free cash flow-$51.3M-$3.31M-$4.33M-$21.2M-$40.6M
Capital expenditure$297,000$0$0$0$0
Total debt$1.27M$0$0$0$0

Quarterly statements and history in the cockpit →

Korsana Biosciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%+20%688319KLRAPGENNRIX087010MSB2637VIRURGN688765PPGN688105QURE6949688222ALVOANIPABSIKRSA6-month return →1-month return →
Up and to the right = strong over both horizons. Korsana Biosciences is the large dot.

Fundamentals: revenue growth against valuation

0%+1,000%+2,000%0×500×1,000×1,500×688319PGENNRIX087010MSBVIRURGN6887656949ABSIKRSARevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Korsana Biosciences is the large dot.

Korsana Biosciences competitors and peer comparison

Head to head with its named competitors (KRSA vs LLY vs BIIB vs RO.SW)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Korsana Biosciences KRSA$1.52B+54%-64%-5,277%1,058.7×n/a
Lilly (Eli) LLY$1.30T+36%+46%51%15.6×6.5%
Biogen BIIB$37.2B+34%+2%17%4.4×10.1%
Roche RO.SW$381B+21%-1%31%5.7×1.7%

How Korsana Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Korsana Biosciences against its 20 peers (data as of 18 Nov 2026)
MeasureKRSAPeer medianRank in peer set
1-month return+7.2%-10.9%2nd highest of 21
6-month return+54.3%-6.9%2nd highest of 20
Distance from 52-week high-44.0%-43.2%11th highest of 21
Revenue growth (TTM)-64.1%+25.4%lowest of 19
Operating margin-5,277.3%-5.7%2nd lowest of 19
EV / Sales1,058.7×10.1×2nd most expensive of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Korsana Biosciences KRSAUnited States$1.52B+54%-64%-5,277%1,058.7×n/an/a
Chengdu Olymvax Biopharmaceuticals 688319.SSChina$1.51B-37%+12%8%13.1×n/an/a
TLC BioSciences 7924.TWOTaiwan$1.50Bn/an/an/an/an/an/a
Kailera Therapeutics KLRAUnited States$1.53B-41%n/an/an/an/an/a
Precigen PGENUnited States$1.53B0%+2,388%21%10.1×n/an/a
Nurix Therapeutics NRIXUnited States$1.54B-14%+739%41%0.8×n/an/a
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%359.6×n/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%12.8×n/an/a
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%n/an/an/a
Vir Biotechnology VIRUnited States$1.57B+3%+1,696%-70%4.0×n/an/a
UroGen Pharma URGNUnited States$1.46B-1%+159%-12%6.3×n/an/a
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%205.0×n/an/a
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%2.3×n/an/a
PolyPeptide PPGN.SWSwitzerland$1.61B+7%+22%7%3.4×n/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%4.9×39.4%-2.5%
uniQure QUREUnited States$1.42B-17%+28%-1,027%65.4×n/an/a
PELL Bio-Med Technology 6949.TWTaiwan$1.62B+28%+8%-1,463%1,650.2×n/an/a
Hitgen 688222.SSChina$1.62B-3%+42%27%14.4×33.2%+16.8%
Alvotech ALVOUnited States$1.62B+38%-14%12%6.4×n/an/a
ANI Pharmaceuticals ANIPUnited States$1.62B-13%+26%15%1.7×-7.6%+33.5%
Absci ABSIUnited States$1.41B+65%-47%-9,155%835.7×n/an/a

Questions

Who are Korsana Biosciences's main competitors?
Named competitors: Eli Lilly (Kisunla) (LLY), Biogen/Eisai (Leqembi) (BIIB), Roche (RO.SW). The cockpit's measured peer set (industry) also includes Chengdu Olymvax Biopharmaceuticals (688319.SS), TLC BioSciences (7924.TWO), Kailera Therapeutics (KLRA), Precigen (PGEN), Nurix Therapeutics (NRIX), Peptron (087010.KS).
Is Korsana Biosciences expensive compared with its peers?
On ev / sales it trades at 1,058.7× against a peer median of 10.1×, 2nd most expensive of 18 in its peer set.
How has Korsana Biosciences stock performed?
Over six months to 18 Nov 2026 the shares returned +54.3% against -6.9% for the median peer; over one year +241.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.